Marathon Asset Management Ltd Has $14.33 Million Position in Bio-Rad Laboratories, Inc. $BIO

Marathon Asset Management Ltd lowered its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 8.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 47,292 shares of the medical research company’s stock after selling 4,626 shares during the period. Marathon Asset Management Ltd owned 0.18% of Bio-Rad Laboratories worth $14,329,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Danske Bank A S bought a new stake in Bio-Rad Laboratories during the fourth quarter worth approximately $30,000. Geneos Wealth Management Inc. lifted its position in Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares during the period. Farther Finance Advisors LLC lifted its position in Bio-Rad Laboratories by 76.9% in the fourth quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company’s stock worth $56,000 after purchasing an additional 80 shares during the period. CWM LLC lifted its position in Bio-Rad Laboratories by 82.0% in the third quarter. CWM LLC now owns 202 shares of the medical research company’s stock worth $57,000 after purchasing an additional 91 shares during the period. Finally, UMB Bank n.a. lifted its position in Bio-Rad Laboratories by 24.0% in the third quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock worth $58,000 after purchasing an additional 40 shares during the period. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Shares of BIO opened at $280.56 on Wednesday. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $343.12. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.21 and a quick ratio of 2.37. The company has a market cap of $7.51 billion, a PE ratio of 46.22 and a beta of 1.06. The firm has a 50-day moving average of $273.53 and a 200-day moving average of $292.69.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $1.89 earnings per share for the quarter, missing analysts’ consensus estimates of $1.97 by ($0.08). The business had revenue of $592.10 million for the quarter, compared to analyst estimates of $589.91 million. Bio-Rad Laboratories had a return on equity of 3.56% and a net margin of 6.52%.Bio-Rad Laboratories’s quarterly revenue was up 1.1% compared to the same quarter last year. During the same period last year, the firm earned $2.54 EPS. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Weiss Ratings lowered Bio-Rad Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Citigroup lowered Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $375.00 to $300.00 in a research report on Tuesday, April 7th. Royal Bank Of Canada began coverage on Bio-Rad Laboratories in a research report on Friday, May 15th. They set an “outperform” rating and a $320.00 target price for the company. Finally, Wells Fargo & Company decreased their target price on Bio-Rad Laboratories from $320.00 to $290.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $303.33.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.